| Old Articles: <Older 51681-51690 Newer> |
|---|
 |
The Motley Fool
September 2, 2011
Steve Rosenbush |
Smucker's Shares Are in a Jam The food giant's still reeling from a wave of panic selling.   |
The Motley Fool
September 2, 2011
Brian D. Pacampara |
Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of drugmaker Regeneron Pharmaceuticals popped 10% in intraday trading Friday after The New York Times reported that Roche's age-related macular degeneration treatment Avastin led to vision loss in several California patients. |
The Motley Fool
September 2, 2011
David Lee Smith |
Exxon Blows Past Its Big Oil Peers With Russian deals, gas leadership, and Gulf discoveries, is Big Oil's biggest also its best? |
The Motley Fool
September 2, 2011
David Williamson |
When a Good Idea Goes Bad And with it go AstraZeneca's hopes of differentiation in a generic world. |
The Motley Fool
September 2, 2011
Navjot Kaur |
Coldwater Creek Is Swimming Against the Tide Coldwater Creek posts bigger-than-expected second-quarter losses. |
The Motley Fool
September 2, 2011
Adam J. Crawford |
Brazil Enters the Race to Debase The emerging market hopes to stimulate growth by watering down its currency. For the time being, gold and silver could be a good place to ride out the storm. One thing is for sure: A Brazilian real sure doesn't buy what it used to. |
The Motley Fool
September 2, 2011
Matt Koppenheffer |
This Is How You Can Buy Happiness Are penny stocks the ultimate route to wealth and happiness? |
The Motley Fool
September 2, 2011
Brian Stoffel |
Some Really Bad, No-Good, Awful Advice It's time for me to lick my wounds and learn from my mistakes in stock picking. |
The Motley Fool
September 2, 2011
John Maxfield |
Retail Stocks That Could Make You Rich How the future of retail could make or break your portfolio. |
The Motley Fool
September 2, 2011
Brian Orelli |
Delcath Wants a Do-Over You'd think a drug failing to show an effect would be the worst thing that could happen to a biotech investor, but mixed results are actually much worse. |
| <Older 51681-51690 Newer> Return to current articles. |
